Production of inhaler grade lactose by crystallization : a thesis presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Process Engineering at Massey University
Loading...
Date
2013
DOI
Open Access Location
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Massey University
Rights
The Author
Abstract
This work focused on producing Inhaler grade lactose (IGL) directly by crystallization. IGL is a
high purity lactose excipient meeting a range of precise particle size distribution specifications.
The 50 percent particle size (d50) on a volume basis desired for this work was in the range of 50
to 90 μm, and a span less than 1. IGL is commonly used as a drug carrier in dry particle
inhalers. Typical industrial lactose crystallization produces lactose with a d50 greater than 200
μm and a span of around 2. The large span has been attributed to successive nucleation events
during the growth phase and growth rate dispersion. Costly additional processing is currently
required to produce IGL, generally in the form of sieving and milling.
Initially the crystallization literature was reviewed with a specific focus on alternative methods
for producing a narrow particle size distribution. From this, three methods were
mathematically modelled for their ability to produce IGL. Crystallization in droplets literature
and model predictions showed great potential for targeting a particle size distribution with a
very low span directly from crystallization; however issues arose with scalability and potential
contamination if not using a lactose or water carrier phase. Subsequent crystallization product
stream processing via a hydrocyclone or inclined settler also showed the ability, in theory, to
produce IGL; however both these methods were deemed as additional processing and a novel
crystallization process was desired. This led to the development of the continuous settling
crystallizer (CSC).
The CSC consists of a vertical column, where a pre-nucleated feed stream enters near the
bottom of the column and flows out the top, all under laminar conditions. Inside the column
only growth occurs as additional nucleation is limited by the chosen column conditions. The
CSC incorporates the key elements revealed from the literature for achieving a narrow span of
a single nucleation event and a method to counteract growth rate dispersion. Slow growing
crystals travel further up the column than fast growing crystals before growing to the terminal
particle settling diameter, opposing flow, and settling out from the column and into the
product stream. For a particular fluid velocity, the crystals settle out into the product stream at
the same final particle size. Under laminar flow conditions a parabolic profile occurs across the
column radius and the CSC theoretical model developed predicted a product d50 of 73 μm and
a span of 0.47 for the chosen column conditions.
Lab scale experiments were then carried out for the CSC. The resulting product d50 was in the
desired range of 50 to 90 μm, but the span ranged from 1.4 to 1.5. Column channelling, an
area of high flow and subsequent low flow elsewhere, was suspected as the cause of the
experimental deviations. The theoretical model was modified to include channelling and
predictions matched the experimental product results well. Due to the high level of control
required for the CSC it is recommended that a batch process is designed to efficiently produce
IGL; this would incorporate a single nucleation event and a hydrocyclone cut.
Description
Keywords
Inhaler grade lactose (IGL), Crystallisation, Dry particle inhalers, Lactose